GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zai Lab Ltd (HKSE:09688) » Definitions » Shares Outstanding (Basic Average)

Zai Lab (HKSE:09688) Shares Outstanding (Basic Average) : 1,027 Mil (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Zai Lab Shares Outstanding (Basic Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Zai Lab's average basic shares outstanding for the quarter that ended in Dec. 2024 was 1,027 Mil.


Zai Lab Shares Outstanding (Basic Average) Historical Data

The historical data trend for Zai Lab's Shares Outstanding (Basic Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zai Lab Shares Outstanding (Basic Average) Chart

Zai Lab Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shares Outstanding (Basic Average)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 776.68 929.92 958.07 966.39 989.48

Zai Lab Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shares Outstanding (Basic Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 970.40 973.15 975.94 981.69 1,027.09

Zai Lab Shares Outstanding (Basic Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Zai Lab  (HKSE:09688) Shares Outstanding (Basic Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Zai Lab Shares Outstanding (Basic Average) Related Terms

Thank you for viewing the detailed overview of Zai Lab's Shares Outstanding (Basic Average) provided by GuruFocus.com. Please click on the following links to see related term pages.


Zai Lab Business Description

Industry
Address
4560 Jinke Road, Jinchuang Plaza, Building 1, 4th Floor, Pudong, Shanghai, CHN, 201210
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
Executives
Fmr Llc 2201 Interest of corporation controlled by you
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Du Ying 2101 Beneficial owner
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Wellington Management Group Llp 2102 Investment manager
Janus Henderson Group Plc 2102 Investment manager
Ubs Group Ag 2201 Interest of corporation controlled by you
Qiming Corporate Gp Iv, Ltd.
Qiming Gp Iv, L.p.
Qiming Venture Partners Iv, L.p.
Qm11 Limited
Invesco Advisers, Inc. 2102 Investment manager
Invesco Developing Markets Fund 2106 Person having a security interest in shares
Baillie Gifford & Co 2102 Investment manager
Citigroup Inc. 2502 Approved lending agent

Zai Lab Headlines

No Headlines